Preclinical activity of eltrombopag (sb-497115), an oral, nonpeptide thrombopoietin receptor agonist

Stem Cells

Volumn 27, Issue 2, 2009, Pages 424-430

  Erickson Miller, Connie L ^a   DelOrme, Evelyne ^b   Tian, Shin Shay ^b   Hopson, Christopher B ^a   Landis, Amy J ^a   Valoret, Elizabeth I ^a   Sellers, Teresa S ^a   Rosen, Jon ^b   Miller, Stephen G ^b   Luengo, Juan I ^a   Duffy, Kevin J ^a   Jenkins, Julian M ^a  

^a GLAXOSMITHKLINE   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

Differentiation; Megakaryocyte; Thrombocytopenia; Thrombopoietin receptor agonist

Indexed keywords

CASPASE 3; CASPASE 7; CD34 ANTIGEN; ELTROMBOPAG; FIBRINOGEN RECEPTOR; STAT PROTEIN; STAT5 PROTEIN; THROMBOPOIETIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHIMPANZEE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MAXIMUM PLASMA CONCENTRATION; MEGAKARYOCYTE; MONKEY; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

ANIMALS; ANTIGENS, CD34; BENZOIC ACIDS; BLOTTING, WESTERN; BONE MARROW CELLS; CASPASE 3; CASPASE 7; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; HYDRAZINES; MEGAKARYOCYTES; MICE; MOLECULAR STRUCTURE; PAN TROGLODYTES; PLATELET MEMBRANE GLYCOPROTEIN IIB; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION;

PAN;

EID: 62549153611     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0366     Document Type: Article

References (31)

1. Paquette RL. Diagnosis and management of aplastic anemia and myclodysplaslic syndrome. Oncology (Williston Park) 2002; 16(suppl 10):153-161.
2. Stevens W, Koene H, Zwaginga JJ et al. Chronic Idiopathic Thrombocytopenic purpura: Present strategy, guidelines and new insights. Neth J Med 2006;64:356-363.
3. Tijssen MR, van der School CE, Voermans C et al. Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy. Transfus Med Rev 2006;20:253-293.
4. Giannini EG. Review article: Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006;23: 1055-1065.
5. Bordin G. Ballare M Zigrossi P et al. A laboratory and thromhokinetic study of HCV-associated thrombocytopenia: A direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995;13(suppl 13):S39-S43.
6. Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: The primary regulator of platelet production. Oncogene 2002;21:3359-3367.
7. Kilter DJ, Begley CG. Recombinant human thrombopoietin: Basic biology and evaluation of clinical studies. Blood 2002;100:3457-3469.
8. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995;374:48-52.
9. Drachman JG, Millet KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem 1999;274: 13480-13484.
10. Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the milogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: Role in endomitosis. Blood 1999;94:1273-1282.
11. Bartley TD, Bogenberger J, Hunt P et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994;77:1117-1124.
12. de Sanvage FJ, Hass PE, Spencer SD et al. Stimulation of megakaryocyto-poiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533-538.
13. Kaushansky K, Lok S, Holly RD et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-571.
14. Lok S, Kaushansky K, Holly RD et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565-568.
15. Wendling F, Maraskovsky E, Debili N et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994;369:571-574.
16. Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241-3248.
17. Erickson-Miller CL, DeLorme E, Tian SS et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005;33:85-93.
18. Duffy KJ, Darcy MG, Delorme E et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem 2001;44:3730-3745.
19. Duffy KJ, Shaw AN, Delorme E et al. Identification of a pharmacophore for thrombopoietie activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem 2002;45:3573-3575.
20. Duffy KJ, Price AT, Delorme E et al. Identification of a pharmacophore for thrombopoietie activity of small, non-peptidyl molecules. 2. Rational design of naphtho[l .2-d]imidazole thrombopoietin mimics. J Med Chem 2002;45:3576-3578.
21. Erickson-Miller C, DeLorme E, Iskandar M et al. Species specificity and receptor domain interaction of a small molecule TpoR agonist. Blood 2004; 104:2909.
22. Nakamura T, Miyakawa Y, Miyamura A et al. A novel nonpelidyl human c-Mpl activator stimulates human megakaryocytopoiesis and thrombosis. Blood 2006:107:4300-4307.
23. Kim M-J, Park SH, Opella SJ et al. NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem 2007;282:14253-14261.
24. Erhardt J, Tapley P, Erickson-Miller, C. A low molecular weight, orally active TpoR agonist, SB-497115, does not prime platelets for activation or agonist-induced aggregation in vitro. Exper Hematol 2005:33(1 suppl):365.
25. Jenkins JM, Williams D, Deng Y et al. Phase I clinical study of eltrombopag. an oral, nonpeptide thrombopoietin receptor agonist Blood 2007; 109:4739-4741.
26. Harker LA, Marzec UM, Hunt P et al. Dose-response effects of pegylatcd human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996;88:511-521.
27. Harker LA, Roskos LK, Marzec UM et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000; 95:2514-2522.
28. Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357: 2237-2247.
29. Kantaijian HM, Giles FJ, Fenaux P et al. Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with my-elodysplastic syndrome (MDS): Preliminary results of a phase 1/2 study. J Clin Oncol 2007;25(18 suppl):7032.
30. McFIutchison JG. Dusbeiko G, Shiftman ML et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-2236.
31. Duffy KJ, Firickson-Miller CL. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In: Metcalf BW, Dillon S, eds. Target Validation in Drug Discovery. Burlington. MA: Academic Press, 2007:241-254.